Moderna (NASDAQ:MRNA) Receives Hold Rating from Needham & Company LLC

Key Points

• Needham & Company LLC has restated a hold rating for Moderna's stock, indicating a cautious outlook for investors.
• Moderna's most recent earnings report showed a loss of ($2.13) per share, with a quarterly revenue of $142 million, which was above expectations but down 41.1% from the previous year.
• The current consensus rating for Moderna's stock is "Hold" with an average target price of $39.93, amidst mixed ratings from several analysts.

Moderna (NASDAQ:MRNA - Get Free Report)'s stock had its "hold" rating restated by Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports.

MRNA has been the subject of several other research reports. JPMorgan Chase & Co. set a $26.00 price objective on Moderna in a research report on Friday, August 1st. Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Barclays lowered their price objective on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research report on Monday, August 4th. Bank of America lowered their price objective on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. Finally, Cowen initiated coverage on Moderna in a research report on Sunday, July 13th. They issued a "hold" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $39.93.

Moderna Stock Performance

Shares of Moderna stock opened at $26.01 on Monday. Moderna has a 52-week low of $23.15 and a 52-week high of $57.69. The stock has a market capitalization of $10.16 billion, a price-to-earnings ratio of -3.45 and a beta of 2.01. The company's 50 day moving average price is $25.91 and its 200-day moving average price is $27.10.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Moderna will post -9.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in shares of Moderna by 1.8% during the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock valued at $54,382,000 after purchasing an additional 34,034 shares during the period. Wealthfront Advisers LLC grew its stake in shares of Moderna by 143.3% during the 1st quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company's stock valued at $879,000 after purchasing an additional 18,268 shares during the period. FORA Capital LLC grew its stake in shares of Moderna by 31.7% during the 1st quarter. FORA Capital LLC now owns 97,072 shares of the company's stock valued at $2,752,000 after purchasing an additional 23,344 shares during the period. Jump Financial LLC grew its stake in shares of Moderna by 5,590.0% during the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company's stock valued at $25,584,000 after purchasing an additional 886,567 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Moderna by 12.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after purchasing an additional 285,662 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.